What the new Spain guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Practice Dispatch
What the new Brazil guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The pharmacy regulator in Brazil has issued counselling standards for initiation of GLP-1 receptor agonist therapy, specifying what must be covered at the point of supply: device technique, expected adverse effects, what to do about a missed dose, storage, sharps disposal, and — notably — what happens if treatment stops.
The titration document sets out three permissible responses to unresolved symptoms at a given dose: hold at the current dose for a further interval, return to the previous dose, or discontinue. It declines to specify a maximum hold duration, on the stated grounds that no evidence supports one.
The evidence base for most practical questions in this field is thin, and the better guidance documents say so explicitly rather than manufacturing a recommendation grade. The Journal reports the stated evidence quality alongside the recommendation, because a strong recommendation on low-quality evidence is a different object from a strong recommendation on high-quality evidence.
Peter Malinowski, former state board of pharmacy inspector, noted who the document does not reach. "None of my patients who buy online will ever see this. That population is entirely outside the guidance system."
The Journal has added the document to its practice index with the stated evidence grades recorded. We report guidance from the document, not from the accompanying summary.
Related coverage
The lowest effective dose is a real concept with almost no data behind it
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
Antiemetics, laxatives and the thin literature underneath them
Dietary measures are widely recommended, plausible on mechanism, and supported mainly by observational data and clinical experience.
The site you keep using is the site that stops working
Repeated injection into the same small area produces lipohypertrophy — thickened, rubbery subcutaneous tissue with blunted and erratic absorption. It is common, it is…
The effect profile, predicted from an expression map
A single drug producing both constipation and diarrhoea looks contradictory until the motility data is read properly.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.